Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
XERS 10.31.2024
Drug:Gvoke-001 Gvoke®
Drug:Keveyis-001 Keveyis®
Drug:Recorlev-001 Recorlev®
Diseases:severe hypoglycemia
Diseases:primary periodic paralysis
Diseases:endogenous Cushing’s syndrome
Date of Upcoming Event:2024-11-08
Name of Upcoming Event:Conference call and webcast
About Gravity Analytica
Conference call and webcast at
To pre-register for the call, please go to the following link:https://www.netroadshow.com/events/login?show=6c5018a9&confId=72180. After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until
To join the webcast, please visit “Events” on investor relations page of the Company’s website atwww.xerispharma.comor use this link:https://events.q4inc.com/attendee/232807470
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, a proven therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris has a diverse pipeline of development and partnered programs using its formulation sciences, XeriSolTM and XeriJect®, to support long-term product development and commercial success.
View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241031125180/en/
Source: